Please login to the form below

Not currently logged in

FDA approves extended use of Actemra

The US Food and Drug Administration (FDA) has extended the label on Genentech's Actemra (tocilizumab) to include three additional uses

The US Food and Drug Administration (FDA) has extended the label on Genentech's Actemra (tocilizumab) to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis (RA), when given in combination with methotrexate (MTX).

"This FDA approval further supports the efficacy of Actemra and follows a similar approval in the EU," said Dr Hal Barron, chief medical officer and head, global product development, Genentech. "For those who are faced with the daily challenges of RA, inhibition and slowing of joint damage is imperative if patients are to truly achieve their treatment goals."

The US licence extension was based on positive data from the phase III LITHE trial which demonstrated that patients receiving either a 4 mg/kg or 8 mg/kg dose of Actemra in combination with MTX had significantly less damage to their joints at one year, compared to patients in the control group. The outcome was determined by X-rays which measured the progression of bone erosions and narrowing of joint spaces over time.

The randomised, double-blind, placebo-controlled LITHE study also showed that patients receiving either dose of Actemra plus MTX showed significant improvement in physical function, compared with patients who received MTX plus placebo at week 52. More patients treated with ACTEMRA also achieved major clinical response, defined as achieving an ACR 70 response for a continuous 24-week period, compared to MTX plus placebo. No new or unexpected safety signals were identified with ACTEMRA, and safety was consistent with previous studies.

The FDA first approved Actemra on January 8, 2010 as the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody to treat moderately to severe active RA in adult patients after an inadequate response to one or more tumour necrosis factor (TNF) antagonist therapies. It can be used as monotherapy or in combination with MTX or other disease modifying anti-rheumatic drugs (DMARDS).

The treatment is also approved for use in the EU and a growing number of other countries including Australia, Brazil, India, Japan, Mexico and Switzerland. 

6th January 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...